Results 91 to 100 of about 17,271 (194)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
BACKGROUND: Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer.
Andrew Protheroe +55 more
core +1 more source
ObjectivesTo compare the efficacy and safety of three drugs—Apalutamide, Abiraterone, and Bicalutamide—combined with Androgen Deprivation Therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).MethodsWe retrospectively ...
Jiabin Zhang +5 more
doaj +1 more source
Introduction Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. Case presentation A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started ...
Yoshinori Yanai +3 more
doaj +1 more source
Background: The new generation anti-androgen enzalutamide and the potent CYP17 inhibitor abiraterone have both demonstrated survival benefits in patients with metastatic castration-resistant prostate cancer (CRPC) progressing after docetaxel. Preliminary
Pezaro, C. +9 more
core +1 more source
Androgen dynamics and serum PSA in patients treated with abiraterone acetate
Background: We analyzed the potential of abiraterone acetate (henceforth abiraterone) to reduce androgen levels below lower limits of quantification (LLOQ) and explored the association with changes in PSA decline in metastatic castration-resistant ...
Chandler, DW +8 more
core
An LC-MS/MS method for quantification of the active abiraterone metabolite Δ(4)-abiraterone (D4A) in human plasma [PDF]
Δ(4)-Abiraterone (D4A) is a recently discovered active metabolite of the oral anti-androgen drug abiraterone acetate. For quantification of this metabolite in human plasma, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed ...
Schellens, Jan H M +7 more
core
Currently, there are no predictive markers of response to abiraterone. We calculated neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) at baseline and at 4 and 12 weeks after initiation of abiraterone, and we evaluated prostate ...
Mertsoylu, Huseyin +11 more
core +1 more source
Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability of converting precursor steroids to 5alpha- dihydrotestosterone (DHT), promoting signalling by the androgen receptor and the development of castration ...
Alyamani, Mohammad +19 more
core +1 more source
Introduction: Combination of abiraterone with androgen deprivation therapy (ADT) has better survival outcomes than ADT alone in metastatic Hormone-sensitive prostate cancer (mHSPC) in the Western population.
Swarnendu Mandal +6 more
doaj +1 more source

